Navigation Links
Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology

velo.com/">www.nuvelo.com or by phoning 650-517-8000.

Kirin Brewery's Pharmaceutical Division is committed to providing innovative pharmaceuticals to patients in the field of kidney diseases, cancer (including hematological disorders), immunological diseases, and infectious diseases by using its unique and strong biotechnology. Kirin Brewery's Pharmaceutical Division has established operations in Asian countries and will expand globally including North America and Europe as a specialty pharmaceutical company. For more information on Kirin Brewery's Pharmaceutical Division, please visit its website at http://www.kirin.co.jp/english/index.html.

This press release contains "forward-looking statements," which include statements regarding the potential uses of NU206 to treat various conditions, the timing and progress of Nuvelo's clinical stage and preclinical research programs, and the potential utility of other Nuvelo compounds to treat particular indications, which statements are hereby identified as "forward- looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; and dependence upon strategic partners for the performance of critical activities under collaborative agreements. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Annual Report on Form 10-K for the year ended December 31, 2006 and subsequent filings. We disclaim any intent o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 Perrigo ... commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL ... acquire Perrigo. "Our views of Mylan,s offer ... to be, based on our Board,s careful reflection of ... depend on the limited choices that Mylan has allowed ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Calif., Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... positive preliminary clinical data from its Phase 1 trial ... HIV-infected subjects who are currently on highly active antiretroviral ... suboptimal CD4+ T-cell counts.  The study is designed to ...
... /PRNewswire/ -- Intuity Medical, Inc .™, ... announced that it has secured a $20M credit facility ... and Oxford Finance Corporation . The funds ... commercialize POGO™, a fully-integrated blood glucose monitoring system. ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and ... just $199, patients can currently receive a one hour treatment of this teeth whitening ... it includes a number of unique features that can turn teeth up to nine ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... ... and their families asked to share stories around men,s health issues , ... Minneapolis, Minnesota (PRWEB) June 15, 2009 -- In ... Scoop is calling on men and their family members to share their health-related experiences ...
... , CHICAGO, June 15 The following statement is attributable ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ... honored that President Obama will speak directly to physicians at ... to health reform this year that provides all Americans with ...
... announced today the first commercial, plant-based diamine oxidase (DAO). Dr. ... that this new diamine oxidase is orders of magnitude more ... is available as a lyophilized powder. Price will be $200 ... test assays to detect spoilage by the presence of histamines ...
... To Be Released Tuesday Show Employer Health Mandate Would Help ... , WASHINGTON, June 15 Hundreds of economists will ... nation,s health care system, and health care experts will release ... a conference call with reporters on Tuesday. , , ...
... delivery of gene therapy suppresses tumors in mice , ... able to fight lung cancer using gene therapy delivered by ... lung cancer that were treated with a vaporized viral vector ... than untreated mice. , Researchers also found that treated mice ...
... JOLLA, Calif., June 15 Transdel Pharmaceuticals, Inc. (OTC ... developing non-invasive, topically administered products, announced that they anticipate ... of Ketotransdel(R) during the third quarter of 2009. ... of a randomized, double-blind, placebo controlled trial to evaluate ...
Cached Medicine News:Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 2Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 3Health News:AMA Committed to Health Reform, Welcomes President Obama 2Health News:Coming Soon: Lung-Cancer Spray? 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: